Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 15, 2006Transplant International

Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients

View Full Paper
Ask AI
Bookmark
Share

Authors

FVFlavio VincentiUniversity of California, San FranciscoAAAmado de AndresTBThomas BeckerUniversity Hospital Schleswig-Holstein

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Vincenti et al. (2006) studied this question.

synapsesocial.com/papers/6ab3603bb8ac748de1debdb4https://doi.org/10.1111/j.1432-2277.2006.00321.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential Protocols using Basiliximab versus Anti-Thymocyte Globulins in Renal-Transplant Patients Receiving Mycophenolate Mofetil and Steroids2004 · 194 citations
  2. 2Two‐dose basiliximab compared with two‐dose daclizumab in renal transplantation: a clinical study2006 · 35 citations
  3. 3Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF-containing Triple Therapy2002 · 257 citations
  4. 4Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation2005 · 248 citations
  5. 5Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials2003 · 140 citations